Challinor-Rogers J L, Hay T K, McPherson G A
Baker Medical Research Institute, Prahran, Australia.
Naunyn Schmiedebergs Arch Pharmacol. 1994 Aug;350(2):158-66. doi: 10.1007/BF00241091.
Alinidine, and eight derivatives, were synthesized and tested for their ability to antagonise the actions of the K+ channel opener cromakalim in rat thoracic aorta, and for their ability to induce bradycardia in rat isolated spontaneously beating right atria. Ring segments of rat thoracic aorta were suspended in organ baths to record isometric tension. Tissues were precontracted with K+ (20 mM), and full concentration-relaxation curves constructed to cromakalim (0.01-30 microM) in the absence and presence of increasing concentrations of alinidine/derivative. The majority of the compounds tested caused rightward shifts in the cromakalim concentration-effect curves. Rat spontaneously beating right atria were suspended in organ baths to record rate of contraction. Addition of alinidine/derivative caused a concentration-dependent negative chronotropic response. In terms of structure-activity relationships, increasing the length of the N-allyl side-chain on the alinidine molecule (from 3 carbon (3C), to 5C) resulted in a significant increase in the activity of the compounds as both bradycardic agents and cromakalim antagonists. The most potent compounds in both cases (bradycardic agent and cromakalim antagonist) had no double bond in the side chain. The results suggest that the carbon side-chain influences the activity of alinidine-related compounds both as cromakalim antagonists and as bradycardic agents. However, while similar structure-activity relationships appear to apply for both effects in some instances, there was no significant correlation between the two actions of the alinidine analogues. The results suggest that the ability of alinidine-derivatives to induce bradycardia or to block K+ channels opened by cromakalim can be differentiated on the basis of structure.
合成了阿利尼定及其8种衍生物,并测试了它们拮抗钾通道开放剂克罗卡林对大鼠胸主动脉作用的能力,以及它们在大鼠离体自发搏动右心房中诱导心动过缓的能力。将大鼠胸主动脉环段悬挂于器官浴槽中以记录等长张力。用钾离子(20 mM)预收缩组织,并在不存在和存在递增浓度的阿利尼定/衍生物的情况下构建对克罗卡林(0.01 - 30 μM)的完整浓度 - 松弛曲线。所测试的大多数化合物使克罗卡林浓度 - 效应曲线右移。将大鼠自发搏动的右心房悬挂于器官浴槽中以记录收缩速率。加入阿利尼定/衍生物会引起浓度依赖性的负性变时反应。就构效关系而言,增加阿利尼定分子上N - 烯丙基侧链的长度(从3个碳原子(3C)增加到5C)会导致这些化合物作为心动过缓剂和克罗卡林拮抗剂的活性显著增加。在这两种情况下(心动过缓剂和克罗卡林拮抗剂)最有效的化合物在侧链中没有双键。结果表明,碳侧链会影响阿利尼定相关化合物作为克罗卡林拮抗剂和心动过缓剂的活性。然而,虽然在某些情况下类似的构效关系似乎适用于这两种效应,但阿利尼定类似物的这两种作用之间没有显著相关性。结果表明,阿利尼定衍生物诱导心动过缓或阻断由克罗卡林打开的钾通道的能力可以根据结构进行区分。